Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH.
J Thromb Haemost. 2014 Mar 5;
Authors: Harenberg J, Du S, Weiss C, Krämer R, Hoppensteadt D, Walenga J, The working party: methods to determine apixaban of the Subcommittee on Control of Anticoagulation of the International Society of Thrombosis and Haemostasis
The oral direct factor Xa inhibitor apixaban is approved for prevention of ischemic stroke in patients with atrial fibrillation (1) and for prophylaxis of postoperative venous thromboembolism following elective knee or hip replacement surgery (2). Studies have shown efficacy and safety for patients with acute deep vein thrombosis compared to vitamin-K antagonists (3), and for prolonged prophylaxis of recurrent events compared to placebo (4). Therapy with apixaban is given at fixed daily doses without laboratory guided adjustment. No study has proved the benefit of dose adjustment on clinical outcome (5). This article is protected by copyright. All rights reserved.
PMID: 24597497 [PubMed - as supplied by publisher]